The American Heart Association, IBM Watson Health and wearable data player Welltok have teamed up to develop a solution to help America's largest employers advance workplace health. This will be the first application of Watson's supercomputing powers to cardiovascular health.
Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan's growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.
Canada's Transition Therapeutics is touting positive Phase II data for a once-a-week GLP-1 treatment, triggering a decision point for partner Eli Lilly, which bought into the program in a $247 million deal.
Merck is buying into a Cancer Research U.K. program that targets an enzyme key to the development of cancer and blood disease, wagering as much as $515 million on the effort.
Boston Scientific will support its largest business segment, cardiovascular, by rolling out a cloud-based digital care solution that's aimed at giving hospitals greater insight into their chronic cardiovascular population and patients. To do so, it's teamed up with software giant Accenture.
CRO giant Parexel has inked a new pact with the Optum Life Sciences unit of the nation's largest insurer, UnitedHealth Group, to help lower costs in postapproval studies.
BioClinica's appetite for pacts shows no sign of abating as it announces a new tie-up with Japanese CRO EPS to focus on risk-based monitoring in clinical trials.
Abbott has partnered with Chicago, IL-based Matter, a healthcare technology incubator, in its latest bid to access innovation. The diversified conglomerate, which markets nutrition, diagnostics, established pharmaceutical and medical device products, is under pressure to improve revenue growth and profitability in the wake of its 2013 split from the biopharma R&D-oriented AbbVie.
The University of Southern California Center for Body Computing has teamed with 8 partners to launch a Virtual Care Clinic. The idea with VCC is to create an integrated approach to the use of mobile apps, "virtual" doctors, artificial intelligence, data collection and analysis, as well as diagnostics and wearable sensors to create truly on-demand healthcare.
After disclosing a major restructuring of its medical device business last week, Johnson & Johnson tried to refocus on the future of that group on its annual earnings call. It emphasized doing more deals to acquire platforms for growth, as well as funneling more resources to high revenue growth device groups.